Document Detail

Strategies to achieve coronary arterial plaque stabilization.
MedLine Citation:
PMID:  10341840     Owner:  NLM     Status:  MEDLINE    
Acute coronary syndromes result from fissure, erosion or rupture of a vulnerable atherosclerotic plaque. The characteristics of a vulnerable plaque include a large lipid pool, an abundance of inflammatory cells and mediators, a reduced smooth muscle cell and collagen content and a thin overlying fibrous cap. Potential therapeutic strategies at achieving plaque stabilization have targeted these features. Lipid lowering agents, beta-adrenergic blockers, angiotensin converting enzyme inhibitors and antioxidants have been shown to reduce the incidence of acute coronary syndromes, presumably through plaque stabilization. Matrix metalloproteinase inhibitors as well as macrolide antibiotics and gene therapy approaches show promise in achieving plaque stabilization. The evidence supporting plaque stabilization by these agents and the mechanisms by which these agents stabilize plaques are discussed in detail in this review.
R Rabbani; E J Topol
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular research     Volume:  41     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1999 Feb 
Date Detail:
Created Date:  1999-06-07     Completed Date:  1999-06-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  402-17     Citation Subset:  IM    
Cleveland Clinic Foundation, Department of Cardiology, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anti-Bacterial Agents / therapeutic use
Antilipemic Agents / therapeutic use*
Antioxidants / therapeutic use*
Coronary Artery Disease / therapy*
Gene Therapy
Metalloendopeptidases / therapeutic use
Myocardial Infarction / prevention & control*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Bacterial Agents; 0/Antilipemic Agents; 0/Antioxidants; 0/Macrolides; EC 3.4.24.-/Metalloendopeptidases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular adhesion molecules on vascular smooth muscle cells.
Next Document:  Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspir...